Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
- Description:
Neurotoxin, widely used to produce the 6-OHDA Parkinson’s disease model
Purity:>98%
β-Amyloid Peptide (1-42) (human) (HB9805)
Description:β-Amyloid (1-42) protein fragment. Implicated in Alzheimer's disease.
(+)-Bicuculline (HB0896)
Description:Prototypic, competitive GABAA receptor antagonist
Purity:>98%
(-)-Bicuculline methiodide (HB0893)
Description:Prototypic, competitive GABAA receptor antagonist
Purity:>98%
(-)-Bicuculline methobromide (HB0894)
Description:Prototypic, competitive GABAA receptor antagonist
Purity:>98%
(-)-Bicuculline methochloride (HB0895)
Description:Prototypic, competitive GABAA receptor antagonist
Purity:>98%
Cyclosporin A (HB0220)
Description:Potent calcineurin inhibitor. Inhibits MPTP opening.
Purity:>99%